Unlearn.AI
Generates AI 'digital twins' — patient-level forecasts trained on historical trial data — to reduce control-arm and overall enrollment needs by 25-50% in clinical trials.
This is where the depth lives — everything below is evidence-graded
How the product is positioned
Generates AI 'digital twins' — patient-level forecasts trained on historical trial data — to reduce control-arm and overall enrollment needs by 25-50% in clinical trials.
Our summary of the vendor’s positioning — verbatim claim not yet recordedWhat we found
Level 1 · assistive
Seeded at the rubric default. No independent evidence of end-to-end task completion has been reviewed yet, so the lowest grade applies until it is.
Any human checkpoint here is a product setting, not a regulatory requirement — confirm how it is configured for your deployment.
Graded 2026-08-01 · re-check 2026-11-01
Procurement detail
- Deployment
- saasvendor documentation
- Compliance
- GxP-aligned R&D processesreport dates not disclosed — request before signing
- Integrations
- Clinical trial data management systems (EDC) claim unverified
- Pricing
- customNot publicly listed; per-trial licensing with pharma sponsors.
- Human checkpoint
- Requiredproduct setting
- Named customers
- AbbVie, Johnson & Johnson Innovative Medicinefrom cited sources
Will they still be here?
- Funding
- $50M Series C raised
- Founded
- 2017
- HQ
- San Francisco, USA
Sources
Logo retrieved 2026-08-01from the vendor’s own site · trademark of Unlearn.AI, Inc.
- drugdiscoverytrends.comIndependent · retrieved 2026-08-01
- unlearn.aiVendor-published · retrieved 2026-08-01
Where it’s weak
Regulatory acceptance of AI-generated synthetic control arms is still evolving and trial-specific; not applicable to all disease areas or endpoints.
Corrections
Vendors may submit factual corrections free of charge. We correct facts and publish the change. We do not accept payment to change a grade. Submit a correction →